BiomarkersHumans
Plasma pTau217 as a marker of both the current and future state of amyloid pathology in adults with DS
AAIC 2025 Abstract
Abstract
Background: Potential anti‐amyloid therapy trials for Down syndrome (DS) require PET‐confirmed “amyloid positivity” for inclusion. Disease progression modeling predicts when individuals with low but meaningful amyloid levels will meet enrollment criteria.
The paper
Julie K. Wisch, Ziqiao Jiao, Patrick J. Lao, Beau M. Ances
Show 23 more authors
Natalie C. Edwards, Adam Brickman, Ann D. Cohen, Zinayida Schlachetzki, Melissa E. Petersen, Benjamin L. Handen, Bradley T. Christian, Mark E. Mapstone, H. Diana Rosas, Florence Lai, J. Lee, Sharon J. Krinsky‐McHale, Frederick A. Schmitt, Jordan P. Harp, Christy L. Hom, Ira T. Lott, Sigan L. Hartley, Shahid H. Zaman, Lauren T. Ptomey, Jeffrey Murray Burns, Laura Ibáñez, Michael S. Rafii, Elizabeth Head,Washington University in St. Louis
AAIC 2025 Abstract · 25 Dec 2025 · CC BY
Presented at AAIC 2025
